Pantec Biosolutions AG
🇱🇮Liechtenstein
- Country
- 🇱🇮Liechtenstein
- Ownership
- Holding
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
4
Active:2
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis
Phase 1
- Conditions
- Psoriatic Plaque
- Interventions
- Drug: Laser microporation + topical application of EtanerceptDevice: Laser microporation aloneDrug: Standard of care-daily administration of Daivobet
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Pantec Biosolutions AG
- Target Recruit Count
- 30
- Registration Number
- NCT02999776
- Locations
- 🇨🇭
University Hospital Geneva, Geneva, Switzerland
Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine
Phase 1
Completed
- Conditions
- Influenza in Human
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Pantec Biosolutions AG
- Target Recruit Count
- 20
- Registration Number
- NCT02988739
- Locations
- 🇦🇹
Medical University Vienna, University Clinic for Clinical Pharmacology, Vienna, Austria
News
No news found